^
Association details:
| Biomarker: | PLCG2 mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
Excerpt:
...we dissect evolution of ibrutinib resistance in serial samples from five chronic lymphocytic leukaemia patients. In two patients, we detect BTK-C481S mutation or multiple PLCG2 mutations. The other three patients exhibit an expansion of clones harbouring del(8p) with additional driver mutations (EP300, MLL2 and EIF2A)...
DOI:
https://dx.doi.org/10.1038%2Fncomms11589
Trial ID:
